BB-10901 in Treating Patients With Relapsed and/or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as BB-10901, can block cancer growth in different
ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
help kill them or carry cancer-killing substances to them.
PURPOSE: This phase I trial is studying the side effects and best dose of BB-10901 in
treating patients with relapsed and/or refractory multiple myeloma.